Medicine and Dentistry
Biological Marker
21%
Biopsy
13%
Brain Disease
11%
Brain Metastasis
15%
Brain Tumor
38%
Brainstem
11%
Cancer Cell
11%
Cancer Treatment
11%
Capecitabine
11%
Cediranib
11%
Central Nervous System
20%
Central Nervous System Metastasis
11%
Cervical Spinal Cord
11%
Chemoradiotherapy
12%
Clinical Assessment
11%
Clinical Feature
11%
Disease
24%
Epidermal Growth Factor Receptor
11%
Ganglioglioma
35%
Glioblastoma
100%
Hypofractionated Stereotactic Radiotherapy
11%
Immune Checkpoint Inhibitor
22%
Immune Deficiency
11%
Magnetic Resonance Imaging
52%
Malignant Neoplasm
18%
Meningioma
11%
Methotrexate
12%
Molecular Marker
12%
Motor Neuron Disease
11%
Myositis
11%
Neoplasm
34%
Neurologic Disease
12%
Non-Hodgkin Lymphoma
11%
Overall Survival
17%
Phase I Trials
11%
Primary Central Nervous System Lymphoma
33%
Programmed Death-Ligand 1
12%
Protein Tyrosine Kinase
11%
Radiation Therapy
27%
Radiomics
11%
Retinal Vasculitis
11%
Status Epilepticus
11%
Stem Cell
11%
Surgery
15%
Symptom
13%
Syringomyelia
11%
Treatment Response
11%
Tumor Progression
15%
Tyrosine-Kinase Inhibitor
11%
Vasculotropin A
11%
Keyphrases
AIDS/HIV
11%
Anti-Hu Antibody
11%
Anti-PD-1
11%
Apparent Diffusion Coefficient
16%
Bevacizumab
23%
Brainstem
11%
Breast Cancer
11%
Cancer Cases
11%
Capecitabine
11%
Chemotherapy
13%
CNS Metastases
11%
Compulsive-like Behavior
11%
Concurrent Chemoradiotherapy
11%
Encephalopathy
11%
Glioblastoma
59%
Glioma
12%
Glioma Biomarkers
11%
Glioma Patients
15%
Gradient Boosted Trees
11%
High-dose Methotrexate (HD-MTX)
14%
High-grade Glioma
18%
Immune Heterogeneity
11%
Inflammatory Infiltrate
11%
Interval Change
11%
Low-grade Glioma
13%
Lymphoma
11%
Magnetic Imaging
11%
Magnetic Resonance Imaging
20%
Matrix metalloproteinase-9 (MMP-9)
33%
Motor Neuron Disease
11%
MRI Texture Analysis
11%
Myositis
11%
Neuronal Migration
11%
Newly Diagnosed
14%
Newly Diagnosed Glioblastoma
16%
Notch Pathway
11%
Ocular Presentations
11%
Overall Survival
28%
Phase II Trial
13%
Primary Central Nervous System Lymphoma (PCNSL)
33%
Radiotherapy
29%
Recurrent Glioblastoma
11%
Recurrent Malignant Glioma
11%
Serum Markers
34%
Temozolomide
29%
TRC105
11%
Tumor
25%
Tumor Treatment Fields
11%
Whole Brain Radiotherapy
14%
YKL-40
33%
Neuroscience
Angiogenesis
11%
Behavior (Neuroscience)
13%
Bevacizumab
24%
Brain Tumor
48%
Brainstem
11%
Cancer Immunotherapy
11%
Carcinogenesis
11%
Carotuximab
11%
CD133
13%
CD4
5%
Cediranib
11%
Cell Line
14%
Cell Loss
5%
Cell Proliferation
7%
Central Nervous System
14%
Corpus Callosum
5%
ELISA
8%
Encephalopathy
11%
Epidermal Growth Factor Receptor
19%
Green Fluorescent Protein
10%
Histopathology
11%
Human Immunodeficiency Virus
11%
In Vivo
11%
Isocitrate Dehydrogenase 1
11%
Longitudinal Study
8%
Low-Grade Glioma
13%
Magnetic Resonance Imaging
95%
Magnetic Resonance Imaging
29%
Methotrexate
18%
Methylation
11%
Midbrain
8%
MMP9
33%
Motor Neuron Disease
11%
Natural Killer Cell
5%
Necrosis
11%
Nervous System
5%
Neuronal Migration
11%
Neurotoxicity
10%
Non-Hodgkin Lymphoma
5%
Notch
11%
Obsessive-Compulsive Disorder
11%
Primary Central Nervous System Lymphoma
22%
Radial Glial Cell
11%
Radiation Therapy
48%
Spinal Cord Compression
5%
Status Epilepticus
11%
Stem Cell
11%
Syringomyelia
11%
Temozolomide
35%
Tumor Treating Fields
11%
